Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
![Imatge de Publicacions](/sites/default/files/styles/3_1_small/public/2022-11/Portada_publicacions-petita_0.jpg?h=c6980913&itok=oZMso2V6)
5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
HLA class I supertypes: a revised and updated classification.
The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression.
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
[Position of darunavir in antiretroviral therapy].
Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated.
Fumarate and nitrate reduction (FNR) dependent activation of the Escherichia coli anaerobic ribonucleotide reductase nrdDG promoter.
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
The host-dependent interaction of alpha-importins with influenza PB2 polymerase subunit is required for virus RNA replication.